Clinical trial
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
NCT00912964 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 28, 2009
- Completion date
- April 27, 2010
- Enrollment
- 2,030 (actual)
- Sites
- 151
Conditions
As the registry lists them; a condition with its own page is linked.